DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

POLICY: Inflammatory Conditions – Taltz Drug Quantity Management Policy – Per Days
- Taltz® (ixekizumab subcutaneous injection – Eli Lilly and Company)

REVIEW DATE: 10/17/2022

OVERVIEW

Taltz, an interleukin (IL)-17A antagonist, is indicated for the following uses:[1]

- **Ankylosing spondylitis**, in adults with active disease.
- **Non-radiographic axial spondyloarthritis**, in adults with active disease and objective signs of inflammation.
- **Plaque psoriasis**, in patients ≥ 6 years of age with moderate to severe disease who are candidates for systemic therapy or phototherapy.
- **Psoriatic arthritis**, in adults with active disease.

Dosing

Taltz is administered as a subcutaneous (SC) injection.[1] It is available as an 80 mg/mL solution in a single-dose 1 mL prefilled auto-injector and a single-dose 1 mL prefilled syringe. Taltz is supplied in cartons of one, two, or three auto-injectors and a carton of one prefilled syringe. When a 160 mg dose is needed, two 80 SC injections should be administered at separate sites. Taltz doses of 20 mg or 40 mg must be prepared and administered by a qualified healthcare professional and only the 80 mg/1 mL prefilled syringe should be used. The recommended dose varies by indication:

- **Adult Plaque Psoriasis:** 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg once every 4 weeks.

- **Pediatric Plaque Psoriasis (patients 6 to < 18 years of age):**

Patient's Weight	Starting Dose (Week 0)	Dose Every 4 Weeks Thereafter
> 50 kg	160 mg (two 80 mg injections)	80 mg
25 to 50 kg	80 mg	40 mg
< 25 kg	40 mg	20 mg

- **Psoriatic Arthritis:** 160 mg (two 80 mg injections) at Week 0, followed by 80 mg once every 4 weeks. For psoriatic arthritis patients with coexistent moderate-to-severe plaque psoriasis, use the dosing regimen for plaque psoriasis.

- **Ankylosing Spondylitis:** 160 mg (two 80 mg injections) at Week 0, followed by 80 mg once every 4 weeks.

- **Non-radiographic Axial Spondyloarthritis:** 80 mg once every 4 weeks.

Policy Statement

This Drug Quantity Management program has been developed to manage potential premature dose escalation of Taltz. If the Drug Quantity Management rule is not met at the point of service, coverage will be determined by the Criteria below. Approvals are provided for 1 year in duration, unless otherwise noted below.

Automation: None.

Drug Quantity Limits

Product	Strength and Form	Retail Maximum Quantity per 28 Days	Home Delivery Maximum Quantity per 84 Days
Taltz® (ixekizumab subcutaneous injection)	80 mg/mL prefilled autoinjector	1 autoinjector	3 autoinjectors
	80 mg/mL prefilled syringe	1 syringe	3 syringes

CRITERIA

1. If the patient is ≥ 18 years of age and is initiating treatment for psoriatic arthritis or ankylosing spondylitis, as verified by the absence of claims for Taltz in the past 130 days, approve a one-time override for 2 syringes or 2 autoinjectors at retail or 4 syringes or 4 auto-injectors at home delivery.

2. If the patient is ≥ 18 years of age and is initiating treatment for plaque psoriasis, as verified by the absence of claims for Taltz in the past 130 days, approve a one-time override for 4 syringes or 4 auto-injectors, followed by 2 syringes or 2 autoinjectors per 28 days for up to 84 days at retail or a one-time override for 8 syringes or 8 auto-injectors at home delivery.

3. If the patient is < 18 years of age, weighs > 50 kg, and is initiating treatment for plaque psoriasis, as verified by the absence of claims for Taltz in the past 130 days, approve a one-time override for 2 syringes or 2 auto-injectors at retail or 4 syringes or 4 autoinjectors at home delivery.

REFERENCES

1. Taltz® [prescribing information]. Indianapolis, IN: Eli Lilly; March 2021.